[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-378321-105":59,"doc-detail-378321-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pan-cancer-analysis-identifies-rnf43-prognostic-therapeutic-and-immunological-biomarker","Pan-cancer analysis identifies RNF43 - prognostic, therapeutic and immunological biomarker","","RING finger protein 43 (RNF43) is an E3 ubiquitin ligase mutated across cancers, yet its pan-cancer landscape and its ability to predict tumor immune phenotypes and immunotherapy benefit remain unclear. This study used TCGA RNA-seq, mutation and clinical data, cBioPortal mutation profiling, GSEA pathway analysis, and immune infiltration/immune modulator assessment (ESTIMATE, CIBERSORT, TISIDB), linking RNF43 to prognosis, immune signatures, MSI, TMB, immunotherapy response and drug sensitivity, with IHC validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-identifies-rnf43-prognostic-therapeutic-and-immunological-biomarker/378321/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-identifies-rnf43-prognostic-therapeutic-and-immunological-biomarker/378321.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is RNF43 and why was it studied in pan-cancer?","Question",{"text":112,"@type":113},"RNF43 is an E3 ubiquitin ligase whose homologous gene is mutated in several cancers. The study focuses on defining its pan-cancer expression pattern and predictive value for prognosis and immune-related outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were RNF43 associations with prognosis and immune features analyzed?",{"text":117,"@type":113},"The research used TCGA RNA-seq, mutation and clinical data to assess RNF43 expression and prognostic significance, cBioPortal to display genetic alterations, GSEA to explore RNF43-modulated pathways, and ESTIMATE/CIBERSORT/TISIDB to interpret links to immune infiltration and immune modulators.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find regarding immunotherapy response and drug sensitivity?",{"text":121,"@type":113},"RNF43 expression correlated significantly with the efficacy of anti-PD-1/PD-L1 treatment and could predict sensitivity to multiple anti-cancer drugs. The paper also validated RNF43 expression differences across cancer types using immunohistochemistry.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},378321,1790730315,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Xu etal. European Journal  \nEuropean Journal of Medical Research (2023) 28:438  \n[https://doi.org/10.1186/s40001-023-01383-1](https://doi.org/10.1186/s40001-023-01383-1 of Medical Research)[ of Medical Research](https://doi.org/10.1186/s40001-023-01383-1 of Medical Research)  \n RESEARCH Open Access  \nPan-cancer analysis identifies RNF43  \nas a prognostic, therapeutic and immunological biomarker  \nYingting Xu1†, Zhengjun Lin1†, Yuqiao Ji1, Chen Zhang4, Xianzhe Tang3, Chuan Li2* and Tang Liu 1*  \nAbstract  \nBackground RING finger protein 43 (RNF43), an E3 ubiquitin ligase, is a homologous gene mutated in several cancers. However, the pan-cancer panoramic picture of RNF43 and its predictive value for tumor immune phenotypesand immunotherapeutic efficacy are still largely unclear. Our study aims to clarify the functions of RNF43 in predicting the prognosis, immune signature, and immunotherapeutic efficacy in pan-cancer.  \nMethods By using RNA-seq, mutation, and clinical data from theTCGA database, the expression levels and prognostic significance of RNF43 in pan-cancer were analyzed. The genetic alteration characteristics of RNF43 were displayed by the cBioPortal database. Gene Set Enrichment Analysis (GSEA) was performed to investigate the potential biological functions and signaling pathways modulated by RNF43 in cancers. The relationship of RNF43 expression with immune cell infiltration, and immune modulators expression was interpreted by the ESTIMATE algorithm, CIBERSORT algorithm, and TISIDB database. The correlations between RNF43, microsatellite instability (MSI), and tumor mutation burden (TMB) were also investigated. Furthermore, the predictive value of RNF43 for immunotherapeutic efficacy and drug sensitivity was further illustrated. Besides, immunohistochemistry (IHC) was employed to validate the expression ofthe RNF43 in different cancer types by our clinical cohorts, including patients with lung cancer, sarcoma, breast cancer, and kidney renal clear cell carcinoma.  \nResults The results demonstrated that RNF43 was abnormally expressed in multiple cancers, and RNF43 is a critical prognosis-related factor in several cancers. RNF43 was frequently mutated in several cancers with a high frequency of 4%, and truncating mutation was the most frequent RNF43 mutation type. RNF43 expression was linked to the abundance of several immune cell types, including CD8+ T cells, B cells, and macrophages within the tumor immune microenvironment. Furthermore, RNF43 expression was significantly correlated with the efficacy of antiPD-1/PD-L1 treatment, and it could predict the sensitivity of various anti-cancer drugs. Finally, IHC explored and validated the different expression levels of RNF43 in different cancers by our clinical samples.  \nConclusion Our results first present the expression pattern and the mutation signature of RNF43, highlighting  \nthat RNF43 is an important prognostic biomarker in pan-cancer. Furthermore, RNF43 seems to be a critical modulator  \n†Yingting Xu and Zhengjun Lin have contributed equally to this work and share first authorship.  \n*Correspondence: Chuan Li[lichuankaka@163.com](lichuankaka@163.com)[ ](lichuankaka@163.com)Tang Liu [liutang1204@csu.edu.cn](liutang1204@csu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by sta","cbCaipNYahgpJqLj","https://ap.wps.com/l/cbCaipNYahgpJqLj","pdf",13552271,21,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is RNF43 and why was it studied in pan-cancer?\",\"answer\":\"RNF43 is an E3 ubiquitin ligase whose homologous gene is mutated in several cancers. The study focuses on defining its pan-cancer expression pattern and predictive value for prognosis and immune-related outcomes.\"},{\"question\":\"How were RNF43 associations with prognosis and immune features analyzed?\",\"answer\":\"The research used TCGA RNA-seq, mutation and clinical data to assess RNF43 expression and prognostic significance, cBioPortal to display genetic alterations, GSEA to explore RNF43-modulated pathways, and ESTIMATE/CIBERSORT/TISIDB to interpret links to immune infiltration and immune modulators.\"},{\"question\":\"What did the study find regarding immunotherapy response and drug sensitivity?\",\"answer\":\"RNF43 expression correlated significantly with the efficacy of anti-PD-1/PD-L1 treatment and could predict sensitivity to multiple anti-cancer drugs. The paper also validated RNF43 expression differences across cancer types using immunohistochemistry.\"}]","Pan-cancer analysis identifies RNF43 - prognostic, therapeutic and immunological biomarker | PDF",1790229522,53]